Effects of a hypo-energetic diet rich in alpha-linolenic acid on body weight, clinical and biochemical parameters in patients with metabolic syndrome

Effects of a hypo-energetic diet rich in alpha-linolenic acid on body weight, clinical and biochemical parameters in patients with metabolic syndrome - MSX study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00006232

Enrollment

Registered

2014-06-12

Start date

2009-01-05

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic syndrome E88.9 (metabolic dysfunction)

Interventions

Group 1: alpha-linolenic acid (3.5 g/day alpha-Linolenic acid for 6 month within a energy-reduced diet

fat intake 38 % of energy

monounsaturated fatty acids 18 % of energy

saturated fatty acids 10 % of energy

energy density 4 kJ/g) Group 2: control (0.9 g/day alpha-Linolenic acid for 6 month within a energy-reduced diet

energy density 4 kJ/g)

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Participants who had the following traits of metabolic syndrome were included: central obesity (waist circumference =94 cm for men and =80 cm for women) plus two of the following criteria (i) fasting serum concentrations of triacylglycerols =1.7 mmol/L, (ii) reduced serum HDL cholesterol (<1.03 mmol/L in men; <1.29 mmol/L in women), (iii) elevated blood pressure (systolic =130 mmHg; diastolic =85 mmHg), (iv) fasting plasma glucose =6.5 mmol/L

Exclusion criteria

Exclusion criteria: smoking; insulin-dependent diabetes mellitus; liver, gastrointestinal, or in?ammatory diseases; a history of cardiovascular events; use of anti-obesity medications or antiin?ammatory drugs; cancer; pregnancy or breast-feeding; alcohol abuse

Design outcomes

Primary

Measure	Time frame
Body weight at study begin and after 3- and 6-month of dietary intervention	—

Secondary

Measure	Time frame
Systolic and diastolic blood pressure, serum lipids and lipoproteins (cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, apolipoprotein B, A1), glucose, insulin, leptin, biomarkers of inflammation (C-reactive protein, tumor-necrosis factor alpha, interleukin 6, fibrinogene, VCAM-1, ICAM-1, E-Selektin, ADMA); all secondary outcomes were measured at the study begin and after 3 and 6 month of dietary intervention	—

Measure

Time frame

Systolic and diastolic blood pressure, serum lipids and lipoproteins (cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, apolipoprotein B, A1), glucose, insulin, leptin, biomarkers of inflammation (C-reactive protein, tumor-necrosis factor alpha, interleukin 6, fibrinogene, VCAM-1, ICAM-1, E-Selektin, ADMA); all secondary outcomes were measured at the study begin and after 3 and 6 month of dietary intervention

—

Countries

Germany

Contacts

Public ContactUrsel Wahrburg

Fachhochschule MünsterFachbereich Oecotrophologie-Facility Management

uwahrburg@fh-muenster.de0251 83-65444

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026